Surrozen, Inc.

Surrozen, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, that is developing antibody therapeutics designed to restore and repair tissue, with a current focus on ophthalmic diseases. The company was founded by scientific leaders who helped uncover the fundamental biology of Wnt signaling, a pathway that regulates stem cell renewal, cell fate, and tissue structure, function, and repair. Building on that legacy, Surrozen created a proprietary antibody-engineering platform to discover multifunctional antibodies that precisely modulate Wnt signaling and other pathways implicated in disease. Surrozen's pipeline is focused on ophthalmic conditions with significant unmet medical need, including diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. Its drug candidates are intended to have best-in-disease potential by addressing the underlying drivers of disease rather than only managing symptoms. The company describes its mission as helping patients preserve and regain the ability to see the people and moments that matter most. Surrozen is led by Chief Executive Officer Craig Parker, with a management team that includes Chief Operating Officer Charles Williams, Executive Vice President of Research Yang Li, PhD, Chief Financial Officer Andrew Maleki, Vice President and Head of Clinical Development Dan Chao, MD, PhD, Senior Vice President of Development Operations Michael Lauw, MSW, and Vice President of Business Development and Corporate Strategy Jeff Ho, MBA. The board of directors is chaired by David J. Woodhouse, PhD, and includes Craig Parker, Anna Berkenblit, MD, MMS, Chris Chai, Mary Haak-Frendscho, PhD, Mace Rothenberg, MD, Eric Bjerkholt, and Tim Kutzkey, PhD. Scientific advisors include K. Christopher Garcia, PhD, Calvin Kuo, MD, PhD, and Roel Nusse, PhD. As a public company, Surrozen maintains corporate governance structures including audit, compensation, and nominating and corporate governance committees, and publishes corporate governance guidelines and a code of business conduct and ethics. The company reports progress through press releases, including an announcement in September 2026 of the submission of an investigational new drug application for SZN-8141 for the treatment of diabetic macular edema.

Surrozen was founded by scientific leaders who uncovered the fundamental biology of Wnt signaling, a key pathway that orchestrates tissue repair and regeneration. Wnt signaling is one of the central regulators of stem cell renewal and cell fate, as well as tissue structure, function, and repair. Building on this legacy, Surrozen scientists uncovered fundamental insights into how to precisely modulate the Wnt pathway, a key signaling cascade of tissue repair and vascular integrity. These advances led to the development of the company's proprietary antibody-engineering platform, which creates multifunctional antibodies capable of Wnt pathway modulation while also addressing other pathways implicated in disease. The company is based in South San Francisco, California, and operates as a public company with corporate governance structures including audit, compensation, and nominating and corporate governance committees. Its scientific advisors include K. Christopher Garcia, PhD, Calvin Kuo, MD, PhD, and Roel Nusse, PhD. Surrozen's current drug candidates target ophthalmic diseases with high unmet needs and are described as having best-in-disease potential. The pipeline addresses diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. In September 2026, the company announced the submission of an investigational new drug application for SZN-8141 for the treatment of diabetic macular edema, marking a key step in advancing its ophthalmic portfolio into clinical development.

• Surrozen announced the submission of an IND application for SZN-8141 for the treatment of diabetic macular edema.

• Surrozen announced it would present at an upcoming investor conference.

Clinical-stage biotechnology company developing best-in-class multifunctional antibody therapeutics for ophthalmic diseases with high unmet need.

• SZN-8141

  Investigational antibody therapeutic for the treatment of diabetic macular edema.

• Wnt pathway-modulating antibody platform

  Proprietary antibody-engineering platform for discovering multifunctional antibodies that modulate Wnt signaling and other disease pathways.

1. 1Restoring Vision Through the Science of Renewal | Surrozensurrozen.com
2. 2Our Focus on Ophthalmology - About | Surrozensurrozen.com
3. 3Corporate Governance | Surrozensurrozen.com
4. 4Surrozen, Inc. (United States)wikidata.org